25 completed, 13 recruiting, 11 terminated, 7 active not recruiting. 63 Phase 1, 30 Phase 2.
Follow azacytidine: new trials by email Literature Review of azacytidine trials Research Report on azacytidine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma Azacitidine, Belinostat, Biospecimen Collection - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 40 | 2027-01-03 | 2026-10-30 |
| FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia Autologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 TCR/CD8ab-expressing T-cells, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 9 | 2026-12-01 | 2026-10-29 |
| Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) azacytidine, carboplatin, paclitaxel - Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 60 | 2026-11-05 | 2026-11-02 |
| Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia | Phase 1 | Recruiting | OHSU Knight Cancer Institute | 40 | 2026-04-21 | 2026-10-05 |
| A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 12 | 2025-07-30 | 2026-09-29 |
| Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Myelodysplastic Syndrome/Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 | Suspended | City of Hope Medical Center | 20 | 2025-04-25 | 2026-10-20 |
| Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia Azacitidine, Venetoclax, Q702 - Acute Myeloid Leukemia | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 17 | 2025-02-12 | 2026-05-29 |
| Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Recruiting | City of Hope Medical Center | 43 | 2025-01-28 | 2026-07-16 |
| A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias Ziftomenib, Venetoclax, Azacitidine - Refractory Acute Leukemia, Pediatric Relapsed | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 22 | 2024-12-27 | 2026-09-03 |
| Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 1 | Suspended | National Cancer Institute (NCI) | 45 | 2024-12-18 | 2026-08-25 |
| Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Withdrawn | City of Hope Medical Center | 2024-10-09 | 2024-09-19 | |
| Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia Azacitidine, Biospecimen Collection, Bone Marrow Biopsy - Acute Myeloid Leukemia, Myelodysplastic Syndrome/Acute Myeloid Leukemia | Phase 1 | Recruiting | OHSU Knight Cancer Institute | 30 | 2024-08-22 | 2026-06-30 |
| Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia Azacitidine, Tagraxofusp-erzs - Acute Myeloid Leukemia | Phase 1 | Withdrawn | Jonsson Comprehensive Cancer Center | 2024-08-03 | 2024-03-08 | |
| Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia Axatilimab, Azacitidine, Biospecimen Collection - Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Uma Borate | 49 | 2024-08-02 | 2026-08-27 |
| A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML) Azacitidine, Venetoclax, NK Cells - Acute Myeloid Leukemia | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 32 | 2023-10-26 | 2026-06-12 |
| Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies AeroEclipse II Breath Actuated Nebulizer, Bintrafusp alfa, Azacytidine - Sarcomas, Melanomas | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2021-12-14 | 2021-12-17 | |
| Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Azacitidine, Seclidemstat - Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1 | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 24 | 2021-07-07 | 2026-09-18 |
| Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia Azacitidine, Uproleselan, Venetoclax - Acute Myeloid Leukemia | Phase 1 | Terminated | Brian Jonas | 16 | 2021-07-02 | 2026-02-23 |
| Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML SLS009, venetoclax, azacitidine - Hematologic Malignancies | Phase 1 / Phase 2 | Recruiting | Sellas Life Sciences Group | 160 | 2021-05-10 | 2026-09-03 |
| DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia DS-1594b, Azacitidine, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 17 | 2021-03-25 | 2025-05-23 |
Showing 20 of 63. Sign in to see all of them.
Leukemia, Myeloid, Acute (40) · Myelodysplastic Syndromes (20) · Leukemia, Myelomonocytic, Chronic (13) · Leukemia (6) · Myeloproliferative Disorders (6) · Myelodysplastic-Myeloproliferative Diseases (5) · Carcinoma, Non-Small-Cell Lung (4) · Leukemia, Erythroblastic, Acute (4) · Leukemia, Megakaryoblastic, Acute (4) · Congenital Abnormalities (3) · Hematologic Neoplasms (3) · Leukemia, Monocytic, Acute (3) · Leukemia, Myelomonocytic, Acute (3) · Lymphoma (3) · Recurrence (3)
M.D. Anderson Cancer Center (21) · National Cancer Institute (NCI) (14) · City of Hope Medical Center (5) · Fred Hutchinson Cancer Center (2) · OHSU Knight Cancer Institute (2) · Weill Medical College of Cornell University (2) · Albert Einstein College of Medicine (1) · Arog Pharmaceuticals, Inc. (1) · Brenda Cooper, MD (1) · Brian Jonas (1) · Case Comprehensive Cancer Center (1) · Jennifer Saultz (1) · Jonsson Comprehensive Cancer Center (1) · Mayo Clinic (1) · Medical College of Wisconsin (1)
United States (60) · Canada (2) · Australia (1) · China (1) · Hong Kong (1) · Japan (1) · Singapore (1)
David S Schrump, M.D. (2) · Guillermo Garcia-Manero (2) · Guillermo M Bravo (2) · Naval G Daver (2) · Nicholas Short (2) · Peter Martin, MD (2) · Abhishek Maiti, MBBS (1) · Abhishek Maiti, MD (1) · Alison Walker (1) · Amanda Blackmon (1) · Annie P Im (1) · Apostolia-Maria Tsimberidou (1) · Aref Al-Kali (1) · Bart Scott (1) · Brenda Cooper, MD (1)
PMID 19546476, PMID 19652201, PMID 22586682, PMID 24142996, PMID 26577691, PMID 29339403, PMID 32074275, PMID 33636454, PMID 34889407, PMID 35442137, PMID 36063832, PMID 36841758, PMID 37422688, PMID 38277619, PMID 38572562, PMID 38744144, PMID 38775157, PMID 39300320, PMID 40073835, PMID 40513054, PMID 42007254, PMID 42200455
P30CA033572 (5), P30CA016672 (4), P30CA006973 (3), P30CA013330 (2), U01CA070095 (2), N01CM00032 (1), N01CM17103 (1), N01CM62203 (1), N01CM62204 (1), P01CA018029 (1), P30CA015083 (1), P30CA015704 (1), P30CA016058 (1), P30CA060553 (1), P30CA093373 (1)